Addition of CEA antigen encoding sequence into the viral construct allowed cost efficient and quantitative in vivo monitoring of viral gene expression in tumors of ovarian cancer patients that are negative for the CEA cancer antigen. This evidence concerns the gene CEACAM5 and ovarian carcinoma.